Omicron News and Research

RSS

Study shows angiotensin-converting enzyme 2 decoy protein as a promising anti-SARS-CoV-2 agent

Researchers presented a microbody recombinant decoy protein with high affinity to angiotensin-converting enzyme 2 (ACE2) as an option for coronavirus disease 2019 (COVID-19) treatment.

5 Jan 2023

How effective is the bivalent mRNA SARS-CoV-2 vaccine in preventing COVID-19 hospitalizations and deaths?

Researchers examined the effectiveness of the bivalent mRNA vaccine against severe outcomes of COVID-19.

5 Jan 2023

COVID booster shots cut Omicron transmission in closed environments

In a recent paper published in the journal Nature Medicine, researchers in the United States investigated the infectiousness of incarcerated individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron infections in prisons, high-risk settings where transmission is intense.

3 Jan 2023

Study compares effectiveness of Pfizer vs. Moderna booster COVID vaccines after third dose

In a recent scientific paper published in the journal Nature Microbiology, researchers reproduced two target trials using electronic health records (EHRs) of the Department of Veterans Affairs (VA) to compare the effectiveness of the third dose of BNT162b2 or messenger ribonucleic acid (mRNA)-1273 vaccine among United States (US) veterans.

3 Jan 2023

What is the global state of SARS-CoV-2 seroprevalence in children?

Researchers conducted a systematic review to assess global pediatric SARS-CoV-2 seroprevalence.

3 Jan 2023

Phase III trial shows noninferiority of VV116 compared to nirmatrelvir–ritonavir among adults with mild-to-moderate COVID-19 at risk of progression

Researchers presented the results of a phase III randomized controlled trial of oral SARS-CoV-2 antiviral VV116.

3 Jan 2023

Effects of hybrid immunity on humoral immune response following COVID mRNA vaccination in a cohort of essential and frontline workers

Researchers longitudinally evaluated humoral immune responses to the second and third doses of COVID-19 mRNA vaccines among individuals with and without prior history of SARS-CoV-2 infections.

3 Jan 2023

BA.4/BA.5 mutations reduced responsiveness of epitope-specific T cells with original mRNA vaccine

A new study in the journal Viruses examines the phenomenon of breakthrough infections due to the evasion of T-cell immunity by the Omicron BA.4/BA.5 subvariants, showing this to be due to spike gene mutations.

2 Jan 2023

Study demonstrates the benefits of vaccination and boosting in reducing COVID-19 transmission

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by researchers at UC San Francisco that examined transmission between people living in the same cell.

2 Jan 2023

Exploring T cell responses during COVID-19 breakthrough infection

Researchers assessed the de novo and recall T cell responses during coronavirus disease 2019 (COVID-19) breakthrough infection.

28 Dec 2022

A genome-based comparison of SARS-CoV-2 XBB recombinant and its parental lineage

In a recent study posted to the bioRxiv* preprint server, researchers in Italy performed a genome-based comparison of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) XBB recombinant with its parental lineages.

27 Dec 2022

An estimated 19 million US adults living with long-COVID

In a recent study published in the journal Clinical Infectious Diseases, a team of researchers examined the risk factors and prevalence and impact of long coronavirus disease (COVID) among a representative sample of adults in the United States (U.S.) and reported that close to 19 million U.S. adults suffer from long COVID.

26 Dec 2022

Exploring plasma and nasal antibody responses to SARS-CoV-2 infection and vaccination

Researchers evaluated plasma and nasal antibody titers responses induced by natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) vaccinations among United Kingdom (UK) residents.

23 Dec 2022

Hybrid immunity from mRNA vaccines and breakthrough Omicron infections induces stronger immune responses against Omicron BQ.1.1

Researchers evaluated plasma samples from individuals vaccinated with a fourth booster dose of mono- or bivalent mRNA SARS-CoV-2 vaccine to evaluate the recognition and neutralization capacity against the ancestral (D614G) strain and the Omicron BQ.1.1 subvariant.

23 Dec 2022

High efficacy of SARS-CoV-2 vaccines in preventing COVID-19 deaths in children and adolescents

A new study evaluated the effectiveness of coronavirus disease 2019 (COVID-19) vaccines in Argentinian children when severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta and Omicron were predominant.

23 Dec 2022

Beta-containing COVID-19 booster vaccine found to cross-neutralize variants in non-human primates

A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.

23 Dec 2022

Molnupiravir does not reduce hospitalization or deaths in vaccinated adults with COVID-19, but improves recovery

Molnupiravir (taken as an 800mg dose twice daily for five days) does not reduce hospital admissions or deaths in vaccinated adults with COVID-19 infection who are at higher risk of mortality, according to the results of a randomised controlled trial, published in The Lancet journal.

23 Dec 2022

Omicron News and Research

Study shows angiotensin-converting enzyme 2 decoy protein as a promising anti-SARS-CoV-2 agent

How effective is the bivalent mRNA SARS-CoV-2 vaccine in preventing COVID-19 hospitalizations and deaths?

COVID booster shots cut Omicron transmission in closed environments

Study compares effectiveness of Pfizer vs. Moderna booster COVID vaccines after third dose

What is the global state of SARS-CoV-2 seroprevalence in children?

Phase III trial shows noninferiority of VV116 compared to nirmatrelvir–ritonavir among adults with mild-to-moderate COVID-19 at risk of progression

Effects of hybrid immunity on humoral immune response following COVID mRNA vaccination in a cohort of essential and frontline workers

BA.4/BA.5 mutations reduced responsiveness of epitope-specific T cells with original mRNA vaccine

Study demonstrates the benefits of vaccination and boosting in reducing COVID-19 transmission

Exploring T cell responses during COVID-19 breakthrough infection

A genome-based comparison of SARS-CoV-2 XBB recombinant and its parental lineage

An estimated 19 million US adults living with long-COVID

Exploring plasma and nasal antibody responses to SARS-CoV-2 infection and vaccination

Hybrid immunity from mRNA vaccines and breakthrough Omicron infections induces stronger immune responses against Omicron BQ.1.1

High efficacy of SARS-CoV-2 vaccines in preventing COVID-19 deaths in children and adolescents

Beta-containing COVID-19 booster vaccine found to cross-neutralize variants in non-human primates

Molnupiravir does not reduce hospitalization or deaths in vaccinated adults with COVID-19, but improves recovery

Children less likely to transmit infectious particles, study finds

COVID-19 vaccination protects people with B cell lymphoma and multiple myeloma

Bivalent mRNA vaccine is moderately effective in preventing COVID-19

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News